Transgene Biotek Clarifies 'Large Corporate' Status

Transgene Biotek Ltd has officially told the Bombay Stock Exchange (BSE) that it does not meet the criteria to be classified as a 'Large Corporate'.

This status is defined by specific circulars from SEBI (Securities and Exchange Board of India) and BSE concerning fundraising through debt securities.

Key Filing Details

Transgene Biotek Limited formally notified the Bombay Stock Exchange (BSE) on April 13, 2026, that it does not qualify as a 'Large Corporate'. This confirmation references SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 and BSE Circular No. LIST/COM/05/2019-20.

Why This Matters for Fundraising

Not being classified as a 'Large Corporate' exempts Transgene Biotek from specific obligations that larger entities face when raising funds via debt securities. This clarification may affect how the company approaches debt financing and its access to certain capital markets.

Background on 'Large Corporate' Rules

The SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 (November 26, 2018), along with BSE's circular LIST/COM/05/2019-20, established guidelines for identifying 'Large Corporates'. These rules were intended to help major companies access the bond market more easily, reducing their reliance on bank loans. Generally, a 'Large Corporate' is a listed entity with substantial long-term borrowings (initially INR 100 crore, later revised) and a high credit rating ('AA' or above). Such companies are mandated to raise a minimum percentage of their new borrowings through debt securities.

Key Implications

• Regulatory Clarity: Investors and stakeholders now have a clear understanding of Transgene Biotek's position regarding 'Large Corporate' debt fundraising norms.
• Financing Flexibility: The company is not bound by mandates requiring it to raise a minimum portion of its borrowings via debt securities.
• Capital Market Access: While exempt from specific 'Large Corporate' debt issuance mandates, the company's options for accessing capital markets through debt instruments may be more conventional.
• Future Planning: This announcement concerns future fundraising strategies, not existing debt.

Financial Risks to Consider

Transgene Biotek faces significant financial challenges. The company has reported consistent net losses, including INR 0.37 crore for the fourth quarter ending March 31, 2025. It has also recorded negative Return on Equity (ROE) for three consecutive years. High interest and employee costs relative to operating revenue, along with Stockopedia's 'Sucker Stock' classification, point to underlying business and financial risks that could affect its ability to raise capital.

Peer Company Declarations

Transgene Biotek is not the only company to clarify its 'Large Corporate' status. Several other listed entities have recently confirmed they do not meet the criteria, impacting their debt fundraising plans. Companies such as Super Sales India Ltd., Centerac Technologies, and IST Limited have made similar announcements. These instances highlight that meeting SEBI's 'Large Corporate' debt issuance framework requires substantial scale and creditworthiness.

Looking Ahead

• Fundraising Strategy: Investors will monitor future announcements from Transgene Biotek regarding its plans for raising capital, especially through debt.
• Financial Health: Continued attention will be paid to the company's quarterly and annual financial results for signs of improvement or deterioration.
• Regulatory Landscape: Awareness of any potential changes to SEBI's 'Large Corporate' classification rules will be important for companies in the future.